Cann Group Ltd

First Australian patients prescribed with Aurora medical cannabis: Cann Group Ltd.’s (ASX: CAN) stock rose 1.83% on August 16, 2018 after the company prescribed the first Australian patients with Aurora medical cannabis through the Therapeutic Good Administration’s (TGA) Special Access Scheme. The patients can access the medicinal cannabis oils after being approved for treatment through the TGA’s Special Access Scheme or Authorised Prescriber Scheme. CAN has imported the first products from its strategic partner and major shareholder Aurora as sponsor and the product supplied being ‘Aurora 1:1 Drops’ comprised of an equal ratio of THC and CBD. The company will be importing additional supplies of cannabis oil from Aurora in several different formulations. Meanwhile, CAN is executing the plans to develop its own local product. Moreover, IDT Australia Limited has signed a manufacturing agreement with CAN to provide manufacturing support related to medicinal cannabis?based product formulations planned for supply to patients in Australia and overseas. On the other hand, CAN stock has fallen 24.79% in three months as on August 15, 2018 in view of fluctuating sentiments in the sector while the stock is at an attractive level. Therefore, we give a “Buy” recommendation on the stock at the current price of $ 2.780.


Upcoming Milestones (Source: Company Reports)
 

The Hydroponics Company Ltd

THC’s wholly owned subsidiary, Canndeo Limited, has released its first medicinal cannabis product: The Hydroponics Company Ltd.’s (ASX: THC) wholly owned subsidiary, Canndeo Limited, has released its first medicinal cannabis product, which is imported from the company’s European strategic alliance partner, Endoca. The product will be provided through the Medicinal Cannabis Medicines Portal (MCMP) under the Approved Prescriber and Special Access Schemes. Further, the products will be available include Endoca’s CBD and unique CBD+CBDA formulations. The immediate patient can access through the Approved Prescriber and Special Access Schemes. Moreover, THC’s  medicinal cannabis strategy is to import product to the Australian market followed by domestic production using pharmaceuticals manufacturing facility and growing capability. Meanwhile, THC stock has fallen 22.05% in three months as on August 15, 2018. However, as of now, we give a “Hold” recommendation on the stock at the current price of $ 0.515, up over 4% on August 16, 2018.
 

AusCann Group Holdings Ltd

Completed a Successful Pilot Study of Final Dose Cannabinoid Capsules: AusCann Group Holdings Ltd.’s (ASX: AC8) stock skyrocketed 32.52% on August 16, 2018 after the company successfully completed the pilot study of its final dose form for its cannabinoid medicines. AC8 has carried the comprehensive pharmaceutical development project over the past ten months to create an optimal dosage form cannabinoid medicine. The company through its research has developed a unique effective stable oral dose form that will provide consistent and stable dosages of the active cannabinoids with reliable bioavailability. AC8 has also lodged a patent with respect to the intellectual property that it has developed and plans to use it in the production of its first stage cannabinoid pharmaceuticals, targeted to be released in first half of 2019. AC8 has ensured that the international quality standards are incorporated in the design of the product and the manufacturing process. The company is well funded for this project after funds raised from a placement and subsequent share purchase plan last month. Meanwhile, AC8 stock had fallen 44.93% in three months as on August 15, 2018. However, based on the foregoing, we give a “Hold” recommendation on the stock at the current price of $ 1.080.

 
Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.